Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtech Investing: A Survivor’s Game

This article was originally published in Start Up

Executive Summary

At Elsevier Business Intelligence's IN3 conference in October 2012, a panel of venture capital investors talked about the current difficult financing climate for medtech start-ups, although a ray of hope lights the future.

You may also be interested in...



VC Collapse Still Hasn’t Hit Bottom; Firms Seek Safety Of Late-Stage Deals

Limited partners require results in today’s difficult climate. Firms with a sound strategy to take advantage of this current climate can have success. Longitude Capital’s partners say the firm’s late-stage focus helped it secure $385 million for its second fund. Split Rock Partners, meanwhile, remains an active investor in early-stage companies in technology and medical devices, investing from a $300 million fund raised in 2009. However, the firm has adjusted its strategy somewhat since raising that fund. Split Rock now is making direct secondary investments as well. The firm is focusing principally on its own portfolio for opportunities, buying out co-investors or executives who may need liquidity.

The Renal Denervation Buzz: Separating Fact From Myth; Covidien Buys Maya Medical

Renal denervation was clearly the belle of this year’s EuroPCR, with more than a dozen sessions on the topic. In addition, just preceding the meeting, Covidien announced its acquisition of RDN start-up Maya Medical.

The Fogarty Institute For Innovation: A Device Incubator For Difficult Times

Go to any gathering of medical device start-up CEOs and their investors, and beneath a veneer of passionate intensity about individual technology lie concern, anxiety, and in some cases, real pessimism. Central to the debate: is the device innovation model broken? Six years ago, one of the most celebrated device entrepreneurs, Tom Fogarty, MD, working with officials at El Camino Hospital in Mountain View, CA, an independent community hospital located in the heart of the San Francisco device community, launched the Fogarty Institute for Innovation, an initiative designed to help the earliest-stage companies ramp up technology development quickly and efficiently in an effort to minimize, if not eliminate the external challenges. To date, the Institute has started or nurtured five companies.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT037766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel